NCT04970667View on ClinicalTrials.gov

Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

April 30, 2020

Conditions
Emotional DisorderNeurologic Disorder
Interventions
DRUG

Flupentixol melitracen tablets

Patients were treated with Flupentixol and melitracen tablets for 12 weeks

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijin

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT04970667 - Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder | Biotech Hunter | Biotech Hunter